.. A*Superstar, Cytos Biotechnology provide upgrade on Phase 1 clinical trial of H1N1 influenza vaccine Singapore's Agency for Technology, Technology and Study and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer provides been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine applicant predicated on Cytos' proprietary bacteriophage Qbeta virus-like particle technology. In this first Phase 1 scientific trial, the security and immunogenicity of the novel vaccine candidate and its potential to safeguard against H1N1 influenza an infection will end up being evaluated.A child dies of pneumonia every 15 seconds and 98 percent of these deaths are in poor nations, said Dr Julian Lob-Levyt, GAVI CEO. A vaccine to help protect kids from pneumonia provides existed since 2000 but is only available in rich countries. GAVI programs to change that. The most effective way to prevent pneumonia deaths would be to provide easy access to secure and affordable vaccines. Vaccines against two of pneumonia’s common bacterial causes, Hib and pneumococcus, are routinely found in industrialized countries but are not yet available in the majority of the developing world.